Amgen Inc. $AMGN Shares Sold by Diversified Trust Co.

Diversified Trust Co. decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 5.5% in the 4th quarter, Holdings Channel reports. The firm owned 40,349 shares of the medical research company’s stock after selling 2,332 shares during the period. Diversified Trust Co.’s holdings in Amgen were worth $13,207,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of the business. Brighton Jones LLC raised its holdings in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after buying an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC boosted its stake in shares of Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after buying an additional 114 shares during the period. Schnieders Capital Management LLC. grew its holdings in shares of Amgen by 29.3% during the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after buying an additional 5,853 shares during the last quarter. American Century Companies Inc. increased its position in Amgen by 110.9% in the 2nd quarter. American Century Companies Inc. now owns 165,122 shares of the medical research company’s stock valued at $46,104,000 after acquiring an additional 86,815 shares during the period. Finally, Coldstream Capital Management Inc. increased its position in Amgen by 11.1% in the 2nd quarter. Coldstream Capital Management Inc. now owns 19,873 shares of the medical research company’s stock valued at $5,549,000 after acquiring an additional 1,985 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $349.77 on Tuesday. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The company has a 50-day moving average price of $360.77 and a 200 day moving average price of $328.60. The company has a market cap of $188.55 billion, a P/E ratio of 24.58, a PEG ratio of 3.45 and a beta of 0.45. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is currently 70.84%.

Analysts Set New Price Targets

AMGN has been the subject of a number of recent research reports. Cantor Fitzgerald increased their price objective on Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Argus boosted their target price on Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a report on Friday, February 6th. Citigroup upped their price target on Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Leerink Partners reaffirmed a “market perform” rating and set a $355.00 price target on shares of Amgen in a report on Thursday, March 5th. Finally, Mizuho lifted their price objective on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $354.60.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.